Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.733383
Title: Measurement of hepcidin-20, -22, -24, and -25 in human serum by liquid chromatography-high resolution-mass spectrometry and its clinical application
Author: Handley, Simon Alfred
ISNI:       0000 0004 6497 9625
Awarding Body: King's College London
Current Institution: King's College London (University of London)
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Hepcidin-25 is regarded as the master regulator of iron homeostasis. Three N-truncated isoforms of hepcidin-25 have been identified in human serum; hepcidin-20, -22, and -24, although information is scant as to the serum concentrations of these isoforms. A liquid chromatography-high resolution-mass spectrometry (LC-HR-MS) assay was developed for the simultaneous quantitation of hepcidin isoforms in human serum. Serum (200 μL) was mixed with aqueous formic acid (600 μL), and the supernatant loaded onto a 96-well- SPE-plate. Eluted sample (70 μL) was diluted with deionised water (60 μL) and analysed using LC–HR–MS. Samples previously analysed by a published LC-MS/MS assay were analysed for method comparison. All hepcidin isoforms were quantified in samples from healthy volunteers as controls, and patients with hereditary haemochromatosis (HH), non-alcoholic fatty liver disease (NAFLD), iron deficient anaemia (IDA), anaemia of chronic disease (ACD), and sickle cell anaemia (SCA). Samples were also analysed from individuals with chronic kidney disease (CKD) not requiring haemodialysis, and those pre- and post-haemodialysis. Intra-/inter-assay accuracy and precision were acceptable, calibration was linear (R2 > 0.90, all analytes), and the LLoQ was 1 μg/L (all analytes). There was a good correlation for hepcidin-25 to a published LC-MS/MS assay (y = 0.85x -3.2, R2 = 0.96). Median (range) hepcidin-25 concentrations in controls, and individuals with IDA, SCA, HH, ACD and sepsis were: 8 (1–31), <1 (< 1–2), < 1 (< 1–10), 2 (< 1–15), 60 (10–213), and 92 (11–216) μg/L, respectively. Hepcidin-20, -22, or -24 were not detected in any control sample, but were detected in 30–100 % of all samples at 10–20 % of the hepcidin-25 concentration. Following haemodialysis, all hepcidin isoforms declined by some 35–50 %. Hepcidin-25 was most strongly correlated to hepcidin-24, and less so to hepcidin-22 and -20, in all disease states. The developed method was applicable for clinical use. However, further controlled studies are required to fully evaluate the role of hepcidin-20, -22, and -24 measurement in a clinical setting.
Supervisor: Sharp, Paul Anthony Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.733383  DOI: Not available
Share: